InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500
Debt
Debt-to-Equity RatioN/A
Current Ratio0.92
Quick Ratio0.92
Price-To-Earnings
Trailing P/E Ratio-0.10
Forward P/E Ratio-0.17
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.37 per share
Price / Book0.26
Profitability
EPS (Most Recent Fiscal Year)($18.50)
Net Income$-26,740,000.00
Net MarginsN/A
Return on Equity-412.40%
Return on Assets-181.93%
Miscellaneous
Employees12
Outstanding Shares7,760,000
Market Cap$14.67 million
Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions
What is Invivo Therapeutics' stock symbol?
Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?
Invivo Therapeutics shares reverse split before market open on Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.
How were Invivo Therapeutics' earnings last quarter?
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) issued its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($7.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $7.07. View Invivo Therapeutics' Earnings History.
When is Invivo Therapeutics' next earnings date?
Who are some of Invivo Therapeutics' key competitors?
Some companies that are related to Invivo Therapeutics include CAS Medical Systems (CASM), Neovasc (NVCN), Pro-Dex (PDEX), iCAD (ICAD), Obalon Therapeutics (OBLN), Interpace Diagnostics Group (IDXG), Spectral Medical (EDTXF), Nephros (NEPH), AIT Therapeutics (AITB), PAVmed (PAVM), SANUWAVE Health (SNWV), Lianluo Smart (LLIT), Titan Medical (TMDI), Presbia (LENS) and CELLECT BIOTECH/S (APOP).
Who are Invivo Therapeutics' key executives?
Invivo Therapeutics' management team includes the folowing people:
- Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 60)
- Dr. Robert S. Langer Jr., Co-Founder and Member of Scientific Advisory Board (Age 69)
- Dr. Joseph Philip Vacanti, Co-Founder (Age 69)
- Mr. Jeffrey Modestino, Principal Financial Officer, Principal Accounting Officer & Treasurer
- Mr. William D'Agostino PE, Sr. VP of Operations
Has Invivo Therapeutics been receiving favorable news coverage?
Media coverage about NVIV stock has been trending somewhat positive on Friday, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Invivo Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Invivo Therapeutics.
Who are Invivo Therapeutics' major shareholders?
Which institutional investors are buying Invivo Therapeutics stock?
How do I buy shares of Invivo Therapeutics?
Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invivo Therapeutics' stock price today?
One share of NVIV stock can currently be purchased for approximately $1.94.
How big of a company is Invivo Therapeutics?
Invivo Therapeutics has a market capitalization of $14.67 million. The biotechnology company earns $-26,740,000.00 in net income (profit) each year or ($18.50) on an earnings per share basis. Invivo Therapeutics employs 12 workers across the globe.
How can I contact Invivo Therapeutics?
Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]
MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
